Microbial Determinants of Dementia Risk in Type 2 Diabetics of Mexican Descent
1 other identifier
observational
12
1 country
1
Brief Summary
Type 2 diabetes (T2D) predisposes individuals to neurodegeneration and dementia, including Alzheimer's Disease (AD); yet the link between metabolic and neurodegenerative disorders remains unknown. Here, the investigators will study a well-defined human population with increased prevalence and early onset of both T2D and AD, individuals of Mexican descent living in South Texas. The study will begin to explore the possibility that disruption of the structure of the bacterial community residing in the gut in type 2 diabetic individuals of Mexican descent living in South Texas is directly related to the increased prevalence of early onset AD in this population. In this study, the investigators will perform gene sequencing on DNA isolated from fecal samples to identify and compare the populations of bacteria living in individuals with T2D versus non-diabetic controls. The investigators will analyze the findings to determine if the community structure of the gut microbiome of individuals of Mexican descent with T2D is significantly altered compared to that of non-diabetics within the same population. The investigators' findings could lead to the identification of early indicators of dementia onset as well as novel therapies for treating metabolic and neurodegenerative diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 20, 2020
CompletedFirst Posted
Study publicly available on registry
October 26, 2020
CompletedStudy Start
First participant enrolled
January 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedFebruary 15, 2023
February 1, 2023
1.4 years
October 20, 2020
February 14, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Fecal Microbial Gene Sequencing
Metagenomic 16S ribosomal RNA (rRNA) gene sequencing will be performed on subject samples to determine the presence and measure the relative abundance of operational taxonomic units representative of bacterial genera, species, and strains present in the fecal sample.
Baseline
Secondary Outcomes (3)
Gastrointestinal health as measured by gastrointestinal symptom rating scale
Baseline
Food Preference Questionnaire
Baseline
Neurological History Questionnaire
Baseline
Study Arms (2)
Type 2 Diabetic
Type 2 diabetic individuals of Mexican descent.
Non-diabetic Controls
Non-diabetic individuals of Mexican descent.
Eligibility Criteria
We will study subjects of Mexican descent living in Texas (aged 50-70 years) with a history of type 2 diabetes (T2D) (n=50, anticipated) and non-diabetic controls (aged 50 - 70 years) (n=50, anticipated).
You may qualify if:
- Male or female with a diagnosis of type 2 diabetes.
- Ages 50 to 70 years.
- Mexican descent living in Texas.
- Participant is willing and able to give informed consent for participation in the study.
- Male or female without history of type 2 diabetes.
- Ages 50 to 70 years.
- Mexican descent living in Texas.
- Participant is willing and able to give informed consent for participation in the study.
You may not qualify if:
- Hypertension that is not controlled by greater than 2 medications.
- Chronic kidney disease, CKD greater than 3.
- History of coronary bypass or stint placement.
- Current pregnancy.
- Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease.
- Hypertension that is not controlled by greater than 2 medications.
- Chronic kidney disease, CKD greater than 3.
- History of coronary bypass or stint placement.
- Current pregnancy.
- Subjects with a history of inflammatory bowel disease, Celiac disease or active diverticular disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Texas Medical Branch
Galveston, Texas, 77555, United States
Related Publications (1)
Matz LM, Shah NS, Porterfield L, Stuyck OM, Jochum MD, Kayed R, Taglialatela G, Urban RJ, Buffington SA. Gut pathobiont enrichment observed in a population predisposed to dementia, type 2 diabetics of Mexican descent living in South Texas. Front Microbiomes. 2024;3:10.3389/frmbi.2024.1456642. doi: 10.3389/frmbi.2024.1456642. Epub 2024 Dec 3.
PMID: 40969174DERIVED
Biospecimen
Fecal bacterial DNA specimens will be retained.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shelly Buffington, PhD
University of Texas Medical Branch Galveston
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 20, 2020
First Posted
October 26, 2020
Study Start
January 14, 2021
Primary Completion
May 31, 2022
Study Completion
December 31, 2022
Last Updated
February 15, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will not share
We do not plan to make individual participant data (IPD) available to other researchers.